FR2477015A1 - Composition pharmaceutique a base d'un alcaloide de l'ergot de seigle, a activite regulatrice sur le tonus vasculaire - Google Patents
Composition pharmaceutique a base d'un alcaloide de l'ergot de seigle, a activite regulatrice sur le tonus vasculaire Download PDFInfo
- Publication number
- FR2477015A1 FR2477015A1 FR8004728A FR8004728A FR2477015A1 FR 2477015 A1 FR2477015 A1 FR 2477015A1 FR 8004728 A FR8004728 A FR 8004728A FR 8004728 A FR8004728 A FR 8004728A FR 2477015 A1 FR2477015 A1 FR 2477015A1
- Authority
- FR
- France
- Prior art keywords
- active ingredient
- composition according
- hours
- weight
- alkaloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 8
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 6
- 230000002792 vascular Effects 0.000 title abstract description 3
- 238000000338 in vitro Methods 0.000 claims abstract description 11
- 238000004090 dissolution Methods 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 15
- 229960004704 dihydroergotamine Drugs 0.000 claims description 9
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 5
- 241000221751 Claviceps purpurea Species 0.000 claims description 3
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 claims description 3
- 230000006442 vascular tone Effects 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical group C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 claims description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010047141 Vasodilatation Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N phthalic acid di-n-ethyl ester Natural products CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- -1 sorbitol stearates Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8004728A FR2477015A1 (fr) | 1980-03-03 | 1980-03-03 | Composition pharmaceutique a base d'un alcaloide de l'ergot de seigle, a activite regulatrice sur le tonus vasculaire |
| DE8181400325T DE3161526D1 (en) | 1980-03-03 | 1981-03-03 | Pharmaceutical composition having a regulatory effect on vascular tone |
| EP81400325A EP0036350B1 (fr) | 1980-03-03 | 1981-03-03 | Composition pharmaceutique à activité régulatrice sur le tonus vasculaire |
| AT81400325T ATE5461T1 (de) | 1980-03-03 | 1981-03-03 | Pharmazeutisches praeparat mit regulierender aktivitaet fuer den blutgefaess-tonus. |
| ES500670A ES8405614A1 (es) | 1980-03-03 | 1981-03-03 | Procedimiento de preparar farmacos con liberacion programada de materia activa. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8004728A FR2477015A1 (fr) | 1980-03-03 | 1980-03-03 | Composition pharmaceutique a base d'un alcaloide de l'ergot de seigle, a activite regulatrice sur le tonus vasculaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2477015A1 true FR2477015A1 (fr) | 1981-09-04 |
| FR2477015B1 FR2477015B1 (enExample) | 1983-06-10 |
Family
ID=9239246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8004728A Granted FR2477015A1 (fr) | 1980-03-03 | 1980-03-03 | Composition pharmaceutique a base d'un alcaloide de l'ergot de seigle, a activite regulatrice sur le tonus vasculaire |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0036350B1 (enExample) |
| AT (1) | ATE5461T1 (enExample) |
| DE (1) | DE3161526D1 (enExample) |
| ES (1) | ES8405614A1 (enExample) |
| FR (1) | FR2477015A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266310A (zh) * | 2011-07-21 | 2011-12-07 | 佛山市隆信医药科技有限公司 | 一种甲磺酸二氢麦角毒碱缓释胶囊及其制备方法 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2539989B1 (fr) * | 1983-01-28 | 1985-08-09 | Sanofi Sa | Medicament a liberation programmee associant l'acide acetylsalicylique a la dihydroergotamine |
| DK58983D0 (da) * | 1983-02-11 | 1983-02-11 | Leo Pharm Prod Ltd | Farmaceutisk praeparat |
| DE3710216A1 (de) * | 1987-03-27 | 1988-10-06 | Rentschler Arzneimittel | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen |
| GB9311191D0 (en) * | 1993-05-29 | 1993-07-14 | Danbiosyst Uk | Controlled release drug formulation |
| AT408198B (de) * | 1998-03-25 | 2001-09-25 | Voest Alpine Ind Anlagen | Verfahren zum stranggiessen eines dünnen bandes sowie vorrichtung zur durchführung des verfahrens |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1467976A1 (de) * | 1963-09-18 | 1969-01-16 | Key Pharma | Traegermassen fuer Pharmazeutika und Verfahren zu ihrer Herstellung |
| GB1443923A (en) * | 1972-05-02 | 1976-07-28 | Shepard M | Sustained release compositions |
| GB2025227A (en) * | 1978-07-15 | 1980-01-23 | Boehringer Sohn Ingelheim | Pharmaceutical preparations in retard form |
| FR2453640A1 (fr) * | 1979-04-12 | 1980-11-07 | Labaz | Compositions therapeutiques a usage oral et a liberation programmee du methanesulfonate de dihydroergotamine |
| FR2453642A1 (fr) * | 1979-04-12 | 1980-11-07 | Sanofi Sa | Compositions therapeutiques a usage oral et a liberation programmee du methanesulfonate de dihydroergotoxine |
-
1980
- 1980-03-03 FR FR8004728A patent/FR2477015A1/fr active Granted
-
1981
- 1981-03-03 EP EP81400325A patent/EP0036350B1/fr not_active Expired
- 1981-03-03 ES ES500670A patent/ES8405614A1/es not_active Expired
- 1981-03-03 DE DE8181400325T patent/DE3161526D1/de not_active Expired
- 1981-03-03 AT AT81400325T patent/ATE5461T1/de not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1467976A1 (de) * | 1963-09-18 | 1969-01-16 | Key Pharma | Traegermassen fuer Pharmazeutika und Verfahren zu ihrer Herstellung |
| GB1443923A (en) * | 1972-05-02 | 1976-07-28 | Shepard M | Sustained release compositions |
| GB2025227A (en) * | 1978-07-15 | 1980-01-23 | Boehringer Sohn Ingelheim | Pharmaceutical preparations in retard form |
| FR2453640A1 (fr) * | 1979-04-12 | 1980-11-07 | Labaz | Compositions therapeutiques a usage oral et a liberation programmee du methanesulfonate de dihydroergotamine |
| FR2453642A1 (fr) * | 1979-04-12 | 1980-11-07 | Sanofi Sa | Compositions therapeutiques a usage oral et a liberation programmee du methanesulfonate de dihydroergotoxine |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266310A (zh) * | 2011-07-21 | 2011-12-07 | 佛山市隆信医药科技有限公司 | 一种甲磺酸二氢麦角毒碱缓释胶囊及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES500670A0 (es) | 1984-07-01 |
| EP0036350B1 (fr) | 1983-11-30 |
| FR2477015B1 (enExample) | 1983-06-10 |
| ES8405614A1 (es) | 1984-07-01 |
| EP0036350A1 (fr) | 1981-09-23 |
| ATE5461T1 (de) | 1983-12-15 |
| DE3161526D1 (en) | 1984-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1492511B1 (fr) | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) | |
| EP0613370B1 (fr) | Formulation a base de diltiazem a liberation prolongee | |
| WO2000007568A1 (fr) | Procede de fabrication de particules de gabapentine ou de pregabaline enrobees | |
| CH661434A5 (fr) | Composition pharmaceutique a absorption reglee. | |
| EP1492531B1 (fr) | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiée d'amoxicilline | |
| EP2272506A2 (fr) | Microcapsules a liberation modifiee de principes actifs peu solubles pour administration per os | |
| FR2938431A1 (fr) | Nouvelle composition a base d'acide gamma-hydroxybutyrique | |
| FR2561524A1 (fr) | Comprimes de principes actifs pharmaceutiques a delitement rapide, stables au stockage | |
| LU87208A1 (fr) | Composition permettant d'administrer un medicament sous forme de gelules,d'une poudre ou d'un liquide | |
| EP0318398B1 (fr) | Forme à libération prolongée du diltiazem et son médicament ainsi obtenu | |
| CA2652023A1 (fr) | Nouvelle forme d'administration du racecadotril | |
| CA2625554C (en) | Enteric soft capsule comprising valproic acid | |
| EP1178778A2 (fr) | Granules contenant une substance vegetale et leur procede de preparation | |
| DK164843B (da) | Theophyllin-retardpraeparat og fremgangsmaade til fremstilling heraf | |
| EP0063132B1 (fr) | Nouvelle forme galenique d'administration du metoclopramide, son procede de preparation et medicament comprenant cette nouvelle forme | |
| EP1077687B1 (fr) | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation | |
| FR2477015A1 (fr) | Composition pharmaceutique a base d'un alcaloide de l'ergot de seigle, a activite regulatrice sur le tonus vasculaire | |
| FR2540727A1 (fr) | Nouvelle preparation retard contenant de la n''-cyano-n-4-pyridyl-n'-1,2,2-trimethylpropylguanidine, utile notamment dans le traitement de l'hypertension | |
| CN101340897A (zh) | 兰索拉唑口腔崩解片剂 | |
| EP0117164B1 (fr) | Médicament à libération programmée associant l'acide acétylsalicylique à la dihydroergotamine | |
| EP2640365A1 (fr) | Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament | |
| JPH10502358A (ja) | 作用物質の遊離遅延を伴うカルバマゼピン薬剤 | |
| FR2885526A1 (fr) | Medicament oral a base d'inhibiteur de pompe a protons | |
| FR2556964A1 (fr) | Nouvelles formes galeniques du sulpiride utilisables par voie orale | |
| FR2554718A1 (fr) | Nouvelles formes galeniques du sulpiride utilisables par voie orale |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property |